Compare RMBS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | CORT |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.6B |
| IPO Year | 1997 | N/A |
| Metric | RMBS | CORT |
|---|---|---|
| Price | $94.52 | $80.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $102.00 | ★ $139.00 |
| AVG Volume (30 Days) | ★ 1.5M | 690.9K |
| Earning Date | 02-02-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.64 | N/A |
| EPS | ★ 2.10 | 0.87 |
| Revenue | $678,488,000.00 | ★ $741,172,000.00 |
| Revenue This Year | $29.01 | $23.79 |
| Revenue Next Year | $16.02 | $40.97 |
| P/E Ratio | ★ $44.84 | $100.74 |
| Revenue Growth | ★ 31.05 | 17.92 |
| 52 Week Low | $40.12 | $49.00 |
| 52 Week High | $114.55 | $117.33 |
| Indicator | RMBS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 47.54 |
| Support Level | $92.88 | $81.31 |
| Resistance Level | $107.66 | $89.00 |
| Average True Range (ATR) | 4.32 | 3.22 |
| MACD | -0.21 | 0.10 |
| Stochastic Oscillator | 13.31 | 21.65 |
Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.